Soligenix Announces $7.5 Million Public Offering to Fund Research, Development, and Commercialization Activities.

Soligenix has priced a public offering of 5,555,560 shares of common stock and warrants to purchase up to 5,555,560 shares of common stock at a combined purchase price of $1.35 per share. The offering is expected to raise approximately $7.5 million, which will be used to fund research and development, commercialization activities, working capital, and general corporate purposes. The closing is expected to occur on September 29, 2025.

Soligenix, Inc. (Nasdaq: SNGX) has priced a public offering of 5,555,560 shares of common stock and warrants to purchase up to 5,555,560 shares of common stock at a combined purchase price of $1.35 per share. The offering is expected to raise approximately $7.5 million, which will be used to fund research and development, commercialization activities, working capital, and general corporate purposes. The closing is expected to occur on September 29, 2025 Soligenix Announces Pricing of $7.5 Million Public Offering^[1].

The company, which focuses on developing and commercializing products to treat rare diseases with unmet medical needs, has also agreed to amend certain existing warrants to have a reduced exercise price of $1.35 per share and a commensurate expiration date. The gross proceeds from the offering are expected to be approximately $7.5 million, before deducting placement agent fees and other estimated offering expenses Soligenix Announces Pricing of $7.5 Million Public Offering^[1].

Soligenix's Specialized BioTherapeutics segment is developing HyBryte™ (SGX301 or synthetic hypericin sodium), a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). The company's Public Health Solutions segment includes development programs for RiVax®, a ricin toxin vaccine candidate, and vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax™, a vaccine candidate for the prevention of COVID-19 Soligenix announces pricing of $7.5 million public offering^[2].

The proceeds from this offering will support Soligenix's ongoing clinical trials and commercialization efforts. The company's forward-looking statements include potential market sizes, patient populations, clinical trial enrollment, and the expected timing for closing the offering and the intended use of proceeds. However, these statements are subject to a number of risks, uncertainties, and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements Soligenix Announces Pricing of $7.5 Million Public Offering^[1].